Literature DB >> 7686348

Atypical basal cell hyperplasia of the prostate. Immunophenotypic profile and proposed classification of basal cell proliferations.

L T Devaraj1, D G Bostwick.   

Abstract

Prostatic basal cell proliferations range from focal basal cell hyperplasia (BCH) to florid adenoid basal cell tumor (ABCT). We reviewed 36 cases of basal cell proliferation to evaluate the architectural and cytologic spectrum of these lesions and identified four distinct patterns by light microscopy: BCH, 12 cases, including two cases with stromal sclerosis; atypical BCH with nucleolomegaly, eight cases; basal cell adenoma (BCA), nine cases; and ABCT, seven cases. Twenty-three cases were evaluated immunohistochemically, and all displayed cytoplasmic immunoreactivity in basal cells with basal-cell-specific high-molecular-weight keratin 34 beta E12 but with increased staining in BCH compared with that in BCA and ABCT. Prostate-specific antigen and prostatic acid phosphatase reactivity were seen at least focally in all cases except two cases each of BCA and ABCT. Chromogranin, S-100 protein, and neuron-specific enolase reactivity were rare or negative in all cases. Nucleolar diameter, measured in 18 of the 36 cases, was significantly greater in atypical BCH (mean, 1.96 microns) than in other forms of basal cell proliferation (mean, < 1.0 microns) (P < 0.05). These results indicate that on the basis of light microscopic, immunohistochemical, and morphometric findings, the spectrum of basal cell proliferations in the prostate can be separated into four distinct groups: BCH, atypical BCH, BCA, and ABCT.

Entities:  

Mesh:

Year:  1993        PMID: 7686348     DOI: 10.1097/00000478-199307000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  16 in total

Review 1.  [Non-neoplastic alterations of the prostate. Why should pathologists know them?].

Authors:  A Erbersdobler
Journal:  Pathologe       Date:  2013-09       Impact factor: 1.011

2.  Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma.

Authors:  Y Yang; J Hao; X Liu; B Dalkin; R B Nagle
Journal:  Am J Pathol       Date:  1997-02       Impact factor: 4.307

3.  Prostate pathology case study seminar.

Authors:  R Montironi; E Alexander; D G Bostwick
Journal:  Virchows Arch       Date:  1997-01       Impact factor: 4.064

4.  Simultaneous tumour-like, atypical basal cell hyperplasia and acinar adenocarcinoma of the prostate: a comparative morphological and genetic approach.

Authors:  A M Luebke; T Schlomm; B Gunawan; H Bonkhoff; L Füzesi; A Erbersdobler
Journal:  Virchows Arch       Date:  2005-02-22       Impact factor: 4.064

Review 5.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

Review 6.  Diagnosis of adenocarcinoma in prostate needle biopsy tissue.

Authors:  P A Humphrey
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

7.  Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.

Authors:  O I Turhan; N E Aydin; O Sariyüce; S Ozkan
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

8.  Adenoid-basal cell tumor of the prostate gland. A case report: histomorphologic and immunohistochemical features.

Authors:  Ozden Tulunay; Diclehan Orhan; Cağatay Göğüş; Emre Culha; Yusuf Ziya Müftüoğlu
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 9.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

Review 10.  Prostate cancer progression. Implications of histopathology.

Authors:  J L Ware
Journal:  Am J Pathol       Date:  1994-11       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.